
3 things to know about brain changes during pregnancy
Women's healthFacebookTweetLink
Follow
Editor's note: The podcast Chasing Life With Dr. Sanjay Gupta explores the medical science behind some of life's mysteries big and small. You can listen to episodes here.
Science has pretty well established that the brain isn't static; it changes and adapts throughout our lives in response to life events in a process called neuroplasticity.
Researchers are discovering this is especially true of female brains, which get remodeled significantly during the three Ps: puberty (as do the brains of adolescent males), pregnancy and perimenopause.
All three transitions are a frequent butt of pop-culture jokes: the sulky, risk-taking teenager who only wants to be with friends; the scattered mom-to-be who leaves her cell phone in the fridge and can't remember where she parked the car; and the hormonal middle-aged woman who can't focus and spontaneously combusts with hot flashes.
But far from being laughable, these behavioral stereotypes are the external manifestations of big internal shifts, many of them linked to the effects of fluctuating hormones on the brain.
Cognitive neuroscientist Laura Pritschet, a postdoctoral fellow in the department of psychiatry at the University of Pennsylvania, is fascinated by how female hormones, including estrogen and progesterone, affect the brain's organization and functioning.
'The reason I chose that field is because I was a budding neuroscientist as an undergrad, interested in brain networks and obsessing over how intricate everything was in the brain to simply allow us to have a personality or remember things,' Pritschet told CNN Chief Medical Correspondent Dr. Sanjay Gupta recently, on his podcast Chasing Life.
'At the same time in my personal life, I was surrounded by menopausal women who were talking about their cognitive complaints and their attention issues,' she said. 'I thought we've got to connect these two together and understand this more.'
Pritschet even volunteered as a 'guinea pig' during graduate school, having her brain scanned and blood drawn for 30 days, across two complete reproductive cycles (both on and off birth control pills), to begin to answer the question of how the day-to-day fluctuations in hormones relate to the day-to-day changes in the brain.
Around this time, other researchers were studying what happens in the brain during pregnancy, Pritschet said, looking at the brain before and after gestation. They found many changes, but because the studies took a snapshot approach, many questions were left unanswered.
'If there's a 3 to 5% decrease in total gray matter volume, when is that occurring (during pregnancy), and how is it occurring?' Pritschet asked. 'We're missing huge gaps in what we call this metamorphosis.
'We know that the 40-week gestational window leads to these body adaptations to support the development of the fetus: We have increased plasma volume, immune function change, metabolic rate, oxygen consumption,' she said. 'What does this trajectory look like over gestation?'
To find out, Pritschet and her team tracked the brain changes in one woman, using MRI and blood draws, from pre-conception and fertility treatment throughout her pregnancy to two years postpartum. Their findings were published in the journal Nature Neuroscience in September.
You can listen to the full episode here.
'We saw this reduction in gray matter volume pretty much across the whole brain,' Pritschet explained. 'We saw increased white matter microstructure and ventricle size.' (Quick anatomy lesson: The brain is made up of gray and white matter. Gray matter is where most of the brain's thinking and processing takes place. White matter helps connect the different brain areas, allowing them to communicate with one another.)
'The inflection point was birth,' Pritschet said. 'We saw that those reductions persisted into postpartum, with slight recovery, meaning that certain areas of the brain showed this rise in gray matter volume in early postpartum. Others did not.'
Pritschet said this 'choreographed dance between major features of our brain' is in one respect a physical adaptation to the increased blood flow and swelling that comes with pregnancy.
Additionally, the changes may also be a preparation for the next stage: parenting.
'It's a fine-tuning of circuits,' she explained. 'We know that pregnancy is the lead-up to this time in your life where there's a lot of behavioral adaptation that has to occur, and new cognitive demands, and a new cognitive load.
'And so the idea here is that there is this pruning or this delicate rewiring to make certain networks or to make communication in the brain more efficient to meet the demands that are going to have to occur,' Pritschet said.
This theory is supported by earlier work. 'The first pinnacle papers that came out looking at neuroanatomy in human women from preconception to postpartum found that degree of change in gray matter volume — that sort of reduction — correlated with various … maternal behaviors (such as bonding). Again, that's all correlation,' she said.
'That's an area we need to do a lot more research on, and it needs a lot of context,' she said. 'But you can expect that if there's fine-tuning in these circuits that underlie cognitive or behavioral process, that the more fine-tuning it undergoes, the better performance you're going to have. That's the idea — but it's so much more complicated than that.'
What happens to the brain during pregnancy? Pritschet offers these three insights.
The only constant is change
The body is the outward sign of a lot of inner upheaval.
'Pregnancy is a transformative time in a person's life where the body undergoes rapid physiological adaptations to prepare for motherhood,' Pritschet said via email. 'But pregnancy doesn't just transform the body — it also triggers profound change to the brain and reflects another critical period of brain development.'
She called this remodeling an often-overlooked period of brain development that takes place well into a woman's adulthood.
How alarmed should women be?
Less gray matter may not sound very positive, but it happens for a reason.
'Despite what one might think, these reductions are not a bad thing, and in fact, are to be expected,' Pritschet said, noting that some of the losses are eventually regained. 'This change could indicate a 'fine-tuning' of brain circuits, not unlike what happens to all young adults as they transition through puberty and their brain becomes more specialized.'
These changes could also be a response to the high physiological demands of pregnancy itself, she said, 'showcasing just how adaptive the brain can be.'
These changes could affect future health and behavior
Mapping these changes could open the door to understanding an array of other neurological and behavioral outcomes including postpartum depression, headaches, migraines, epilepsy, stroke and parental behavior.
'The neuroanatomical changes that unfold during (pregnancy) have broad implications for understanding vulnerability to mental health disorders … and individual differences in parental behavior,' said Pritschet.
It may even provide critical insight into how the brain changes over a lifespan, she said.
We hope these insights help you better understand the brain changes that occur during pregnancy. Listen to the full episode here. And join us next week for a new episode of the Chasing Life podcast.
CNN Audio's Lori Galarreta contributed to this report.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
ACHV: Achieve's Busy Day
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted a flurry of press releases last week announcing the submission of its new drug application (NDA), a partnership with Omnicom for cytisinicline commercialization, a proposed public offering and the pricing of the offering. The capital raise was closed on June 30th. This is the culmination of more than a decade of work developing cytisinicline for smoking cessation. Now that the development phase of cytisinicline for smoking cessation is coming to a close, we look towards the regulatory and commercialization phases. We expect to see the FDA formally accept the NDA by late August and Achieve's management team to turn its attention towards the sales effort. Assuming normal turnaround times, we expect the FDA to set a target action date sometime in 2Q:26. NDA Submission Achieve announced its NDA submission of cytisinicline for smoking cessation in a June 26th press release. The company conducted two Phase III studies, an open label safety study and other studies that evaluated over 2,000 participants with the results demonstrating the safety, efficacy and tolerability of cytisinicline. We expect to see acceptance of the NDA within 60 days and further expect additional safety data from the ongoing ORCA-OL trial to be shared with the agency near year end. Commercialization Partnership Now that the new drug application has been submitted, Achieve is further advancing its commercialization efforts. During its earnings calls, the company has outlined its commercialization strategy and is now partnering with Omnicom Group to execute the plan. Omnicom Group provides brand and advertising services to thousands of clients globally and is one of the world's largest advertising and marketing services companies. Achieve will work with Omnicom subsidiary Credera, which is focused on digital transformation services. Credera combines consulting, artificial intelligence (AI) and technology expertise to build consumer technology platforms, integrate marketing technology systems and provide strategic consulting services. It will help Achieve to precisely target and engage healthcare professionals and patients through optimization of channel performance and acceleration of meaningful engagement. The team executing the initiative will include Goodby, Silverstein & Partners, DDB Health, and Ketchum Health which are health care-focused subsidiaries of the Omnicom marketing group. The various subsidiaries will provide expertise in consumer brand development, medical education and strategic public relations and communications, applying industry insights to support cytisinicline launch. In the Achieve partnership, Ketchum Health brings public relations and communications expertise, while Credera handles technology, Goodby Silverstein provides creative advertising, and DDB Health focuses on healthcare marketing. The partnership will use generative AI, predictive analytics and social listening to enhance targeting and personalization. Using a comprehensive approach, it will also employ healthcare applications, pharmacies and data providers to expand the reach and depth of insights. Omnicom has worked as media agency, digital and brand experience for other pharmaceutical and biotechnology clients including established firms such as AbbVie, AstraZeneca, Novartis and Moderna among others. Achieve will be the first small company that Omnicom has supported in commercializing a newly approved drug. Therefore, Omnicom will take on a broader strategic role than in its past partnerships. The Omnicom team will help communicate the optimal message to the provider and patient and monitor its effectiveness in real time. This will allow for rapid course corrections and focus on high value activities. Achieve has identified several target groups for its marketing efforts that are stratified by age, social media use and other demographic data. It was able to identify these groups based on subject experiences in the company's many clinical trials. We anticipate that the structure of Achieve's internal marketing team will be heavily tilted toward supporting the digital campaign with contract representatives available for in-person physician meetings when appropriate. Public Offering On June 30th, 2025 Achieve closed its $45 million capital raise. 15 million shares were issued at $3.00, each of which included an attached warrant exercisable at $3.00 per share. An additional 1,766,666 warrants were issued upon the partial exercise by the underwriters of their option to purchase additional shares, bringing total issued warrants to approximately 16.8 million. Net proceeds from the capital raise are estimated to be $41.3 million as disclosed in the June 27th Form 8-K filing. ORCA-OL Safety Trial Achieve began 2025 by announcing that 300 participants had completed six months of treatment in the Ongoing Research of Cytisinicline for Addiction Program, Open Label (ORCA-OL) trial. The Data Safety Monitoring Committee (DSMC) identified no safety concerns as of this milestone allowing registrational filing with the FDA. As of May 2025, a third DSMC safety review was completed which also found no unexpected treatment-related adverse events. As of the first quarter reporting date, more than 100 subjects had completed one year of cytisinicline treatment. Furthermore, about 75% of the 479 (~360) individuals remained on treatment in the trial. We think that it is a material real-world positive that so many participants would remain on a smoking cessation product for that long a period suggesting that cytisinicline is well tolerated. This is particularly notable given the high discontinuation rates for Chantix and the associated unpleasant side effects such as nausea, headache, abnormal dreams and constipation.[1] Achieve expects to complete the one-year safety data package in the next few months and will submit this to the FDA by the 120-day safety review milestone. This should be around year-end 2025. Achieve expects that it will far exceed the 100-patient minimum required for one year of safety observations and could see as many as 300 patients with one year of exposure. Since one of the secondary endpoints is efficacy, this study should be able to show a wealth of data that can help providers use cytisinicline more effectively especially in chronic areas of disease such as Chronic Obstructive Pulmonary Disease (COPD) and cardiology. Milestones Development of cytisinicline product label for smoking cessation – 1H:25 Completion of six months of ORCA-OL safety data for 300 subjects – January 2025 Attendance at Oppenheimer Healthcare Life Sciences Conference, Virtual – February 2025 Attendance at Barclays Healthcare Conference, Miami – March 2025 Selection of 3rd party logistics partner – 2Q:25 NDA Submission – 2Q:25 FDA data submission from patients with twelve months of exposure to cytisinicline – 4Q:25 Launch of Phase III vaping trial – 1H:26 FDA target action date for cytisinicline NDA – 1H:26 Launch of cytisinicline – 3Q:26 SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer . ________________________ [1] Minian, N., et al. Identifying determinants of varenicline adherence using the Theoretical Domains framework: a rapid review. BMC Public Health. March 2024.
Yahoo
33 minutes ago
- Yahoo
How China is leading the humanoid robots race
I've worked at the bleeding edge of robotics innovation in the United States for almost my entire professional life. Never before have I seen another country advance so quickly. Psychologists now know exactly what makes someone cool. Turns out, the definitions are universal 3% mortgage rates aren't dead—housing market sees 127% increase in buyers taking over old loans There's a reason your Sam's Club rotisserie chicken looks different In the span of the last few years, China has overtaken the U.S. as the leader in the robotics race, especially when it comes to humanoid robots designed to mimic the human body and behavior. Earlier this year China literally raced robots against human counterparts, and they show no sign of slowing down. While AI steals the investment and media spotlight, the competition for humanoid robotics supremacy has been quietly accelerating for 50 years, and we're now on the cusp of a momentous breakthrough. Mass-produced humanoid robots may reach us within the next 3–5 years, and the market is predicted to grow to $38B within just 10 years. China is poised to capture the lion's share of this industry: Morgan Stanley found that 56% of robotics companies are already based there. However, this competition isn't just about market share—it's about industrial supremacy. Fixed industrial robots now operate with productivity rates estimated to be 10 times that of humans, working almost 24/7 with virtually no errors. In this new era of free-moving humanoid robots, adaptable machines will navigate entire factory floors with equal precision and even higher productivity rates than their fixed (and human) counterparts. American companies like Boston Dynamics are building impressive prototypes but those don't win industrial wars, production does. If the U.S. continues to lag behind in the robotics race, American businesses will face increased supply chain dependence on China and citizens could see wage stagnation and job losses to robotics leaders overseas. I witnessed the U.S. lead the world in robotic advancements. Two of my humanoid robots went into space; one called 'Robonaut' now lives in the Smithsonian. Over the past decade, our momentum has slowed. To take back robotics supremacy, the U.S. must overcome four critical hurdles that could cost us this race. Yes, Chinese robotics startups are benefiting from established supply chains, local adoption opportunities, and strong national government support, but nagging domestic problems are holding the United States back, regardless of any other country's advancements. First, we're battling our own cultural fears. There's a prevailing anxiety that robots will replace human jobs, particularly in factories. While massive change in manufacturing is fast approaching, the fear of replacement is not only wrong—it's counterproductive. Humanoid robots excel at 'dirty, dark, and dangerous' jobs that often lack willing human labor anyway. To overcome U.S. cultural fears around robotics, we must think of robots not as standing in our place but standing by our sides. WWII was won as much on the mechanized manufacturing floor as on the battlefield and novel machines were essential to winning the space race. When Robonaut shook hands with a fellow astronaut aboard the International Space Station, it was proof that robots can and should support human work, not compete with it. Second, we're not cultivating the people behind the humanoids. The real challenge in winning the humanoid race isn't job displacement; it's the massive lack of skilled domestic workers to develop, operate, and maintain advanced robotics. At Texas A&M, I teach brilliant students ready to tackle real-world problems with robots. Educating the workforce about how to leverage robots will empower the next generation and dispel fear. However, across the country, preparation for careers in STEM is lacking. We need more accessible science programs, apprenticeships, and pathways into robotics now. Third, the economics still intimidate us. Developing humanoid robots involves significant upfront costs and still faces expensive technical hurdles, including improving spatial awareness and task adaptability. But here's what the bean counters are missing: once mass production kicks in, the cost of robot labor could plummet from $10 to just $0.25 per hour in as little as 10 years. The industry will transform overnight and whichever country controls this shift owns the future of manufacturing. Focusing on the future affordability of robot labor will incentivize both the private and public sector to invest now. Fourth, our policy framework is falling behind. While the U.S. offers some incentives for research and innovation, they pale in comparison to China's commitment. The Chinese government has poured over $20 billion into robotics and next-generation technologies, providing subsidies for startups and covering costs for equipment and talent acquisition. They're projected to match U.S. robotics research and development levels by 2034. Meanwhile, current U.S. tax code continues to disincentivize longer-term innovation projects by forcing companies to pay more up front for R&D. As the U.S. federal government increasingly overlaps its ambitions with AI tech companies, so too must it champion the development of humanoid robots as a national security and productivity imperative. In tandem with overcoming these inherent challenges, the U.S. must seize two unique opportunities that offer a high return on investment and a clear path to victory. Humanoid robots can maintain our edge in advanced manufacturing. Humanoids integrated with AI and embedded into the internet of things will create smart factories that enhance precision, improve product quality, and accelerate production times. The U.S. currently leads the world in the development of smart textiles—humanoid robots could accelerate production to maintain this advantage. Warehouses offer an arena for rapid humanoid adoption. The number of warehouses across the U.S. continues to expand, with Amazon recently announcing plans for dozens more across rural areas. Our vast network of warehouses is primed for humanoid robots to revolutionize its operations by automating sorting, packing, and transport alongside humans to boost efficiency and slash costs. These aren't theoretical applications: they're already being tested at sites like BMW's South Carolina plant, where robotics partners are deployed for logistics and warehousing tasks. These deployments leverage our existing strengths in technology and innovation while addressing real, immediate market needs. We don't need to wait for the perfect humanoid robot—we can start dominating these sectors today and build from there. This race not just about machines; it's about maintaining U.S. leadership in technology, safety, and industrial strength. If we want the next generation of robotics to serve American interests, we must act now or be left standing on the sidelines of the next industrial revolution. During my two decades at NASA, I saw what American innovators can achieve when given a mission. We sent robots to the Moon, Mars, and into orbit—not because it was easy, but because we believed it mattered for future generations. That same spirit must drive our investment in humanoid robotics today so we can cross the finish line first tomorrow. This post originally appeared at to get the Fast Company newsletter:


CBS News
40 minutes ago
- CBS News
Colorado Medicaid recipient fears losing coverage after "big, beautiful bill" passes
Colorado Medicaid recipient concerned about losing coverage now that "big, beautiful bill" has been Colorado Medicaid recipient concerned about losing coverage now that "big, beautiful bill" has been Colorado Medicaid recipient concerned about losing coverage now that "big, beautiful bill" has been President Trump signed what he called the "One Big Beautiful Bill Act" during a celebratory event on July 4 after the bill narrowly passed the House on Thursday, with Colorado's congressional delegation voting along party lines. The legislation makes a number of changes to domestic policies, including permanently increasing the child tax credit to $2,200, allowing tipped workers to deduct tips and overtime from federal taxes, and boosting funding for U.S. Immigration and Customs Enforcement. It also eliminates tax incentives for clean energy, electric vehicles, and energy efficiency programs. In addition, the bill includes stronger restrictions on Medicaid, which provides health care coverage to over 70 million low-income and disabled Americans, according to data from the U.S. Department of Health and Human Services. Lindsey Schoen, a Colorado resident who got on Medicaid in 2014 after a severe bacterial infection left her unable to work, said she's worried about the changes. "It scares me, not only for myself, but for all of the people who are on Medicaid, who are just trying to survive," she said. Lindsey Schoen, a Colorado resident who got on Medicaid in 2014 after a severe bacterial infection, talks to CBS News Colorado via Zoom about concerns she has about possible cuts to Medicaid after President Trump signed the "One Big Beautiful Bill Act" on July, 4, 2025. CBS Schoen said the coverage helped her regain her health and return to work. "Because of Medicaid, I've been able to get well enough to actually work again," Schoen said. "I work for the State of Colorado, for the Division of Youth Services, and I love my job so much." One in four Coloradans receives Medicaid benefits -- about 1.72 million people, according to the Colorado Department of Health Care Policy and Financing. Annie Lee, president and CEO of Colorado Access, which helps administer Medicaid in the state, said the new bill could have a sweeping effect. "What this bill does is really shift the financial burden to states," Lee said. "The majority of the things in the bill that was just passed are set to take effect next year or the following year. There's kind of a graduated impact for most of the things in the bill." Stretchers for an operating room are seen at Denver Health in Denver, Colorado on Thursday, April 25, 2024. Hyoung Chang/The Denver Post via Getty Images The legislation adds work requirements for certain adults to keep receiving Medicaid benefits. Supporters argue it will motivate able-bodied adults to improve their lives. But Schoen said many Medicaid recipients already work. "A lot of us do work. We try really hard. We don't just lie around on the couch all day," she said. "I was hospitalized seven times last year, and I had two surgeries, and I worked the entire time. But there are many times where it just feels like I'm walking on thin ice. If one more thing happens, the whole house of cards could just collapse." Lee warned the bill is anticipated to result in "large-scale loss of health insurance coverage for Coloradans." Schoen echoed that concern. "I just feel like the people who we've elected to be our proxies have just turned around and pushed us off a cliff," she said. "And there's no safety net down there."